帕利单抗预防严重呼吸道合胞病毒(RSV)疾病的安全性、有效性和耐受性综述。

IF 2.2 Q2 HEALTH CARE SCIENCES & SERVICES Drug, Healthcare and Patient Safety Pub Date : 2023-09-11 eCollection Date: 2023-01-01 DOI:10.2147/DHPS.S348727
Shaun O'Hagan, Niamh Galway, Michael D Shields, Peter Mallett, Helen E Groves
{"title":"帕利单抗预防严重呼吸道合胞病毒(RSV)疾病的安全性、有效性和耐受性综述。","authors":"Shaun O'Hagan,&nbsp;Niamh Galway,&nbsp;Michael D Shields,&nbsp;Peter Mallett,&nbsp;Helen E Groves","doi":"10.2147/DHPS.S348727","DOIUrl":null,"url":null,"abstract":"<p><p>Respiratory Syncytial Virus (RSV) is a major global cause of childhood morbidity and mortality. Palivizumab, a monoclonal antibody that provides passive immunity against RSV, is currently licensed for prophylactic use in specific \"high-risk\" populations, including congenital heart disease, bronchopulmonary dysplasia and prematurity. Available research suggests palivizumab use in these high-risk populations can lead to a reduction in RSV-related hospitalization. However, palivizumab has not been demonstrated to reduce mortality, adverse events or length of hospital stay related to RSV. In this article, we review the management of RSV, indications for palivizumab prophylaxis, the safety, cost-effectiveness and efficacy of this preventative medication, and emerging therapeutics that could revolutionize future prevention of this significant pathogen.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"15 ","pages":"103-112"},"PeriodicalIF":2.2000,"publicationDate":"2023-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/60/b2/dhps-15-103.PMC10503506.pdf","citationCount":"0","resultStr":"{\"title\":\"Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease.\",\"authors\":\"Shaun O'Hagan,&nbsp;Niamh Galway,&nbsp;Michael D Shields,&nbsp;Peter Mallett,&nbsp;Helen E Groves\",\"doi\":\"10.2147/DHPS.S348727\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Respiratory Syncytial Virus (RSV) is a major global cause of childhood morbidity and mortality. Palivizumab, a monoclonal antibody that provides passive immunity against RSV, is currently licensed for prophylactic use in specific \\\"high-risk\\\" populations, including congenital heart disease, bronchopulmonary dysplasia and prematurity. Available research suggests palivizumab use in these high-risk populations can lead to a reduction in RSV-related hospitalization. However, palivizumab has not been demonstrated to reduce mortality, adverse events or length of hospital stay related to RSV. In this article, we review the management of RSV, indications for palivizumab prophylaxis, the safety, cost-effectiveness and efficacy of this preventative medication, and emerging therapeutics that could revolutionize future prevention of this significant pathogen.</p>\",\"PeriodicalId\":11377,\"journal\":{\"name\":\"Drug, Healthcare and Patient Safety\",\"volume\":\"15 \",\"pages\":\"103-112\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2023-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/60/b2/dhps-15-103.PMC10503506.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug, Healthcare and Patient Safety\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/DHPS.S348727\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug, Healthcare and Patient Safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/DHPS.S348727","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

呼吸道合胞病毒(RSV)是全球儿童发病率和死亡率的主要原因。帕利单抗是一种提供对呼吸道合胞病毒被动免疫的单克隆抗体,目前已获准在特定的“高危”人群中预防性使用,包括先天性心脏病、支气管肺发育不良和早产。现有研究表明,在这些高危人群中使用帕利单抗可以减少呼吸道合胞病毒相关的住院治疗。然而,帕利单抗尚未被证明可以降低与呼吸道合胞病毒相关的死亡率、不良事件或住院时间。在这篇文章中,我们回顾了呼吸道合胞病毒的管理、帕利单抗预防的适应症、这种预防性药物的安全性、成本效益和疗效,以及可能在未来彻底预防这种重要病原体的新兴疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease.

Respiratory Syncytial Virus (RSV) is a major global cause of childhood morbidity and mortality. Palivizumab, a monoclonal antibody that provides passive immunity against RSV, is currently licensed for prophylactic use in specific "high-risk" populations, including congenital heart disease, bronchopulmonary dysplasia and prematurity. Available research suggests palivizumab use in these high-risk populations can lead to a reduction in RSV-related hospitalization. However, palivizumab has not been demonstrated to reduce mortality, adverse events or length of hospital stay related to RSV. In this article, we review the management of RSV, indications for palivizumab prophylaxis, the safety, cost-effectiveness and efficacy of this preventative medication, and emerging therapeutics that could revolutionize future prevention of this significant pathogen.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Drug, Healthcare and Patient Safety
Drug, Healthcare and Patient Safety HEALTH CARE SCIENCES & SERVICES-
CiteScore
4.10
自引率
0.00%
发文量
24
审稿时长
16 weeks
期刊最新文献
The Impact of Sacubitril/Valsartan on Heart Failure Patient with Reduced Left Ventricular Ejection Fraction: Single Center Retrospective Study in Saudi Arabia. Adverse Events Following Immunization with Novel Oral Polio Vaccine Type 2, and the Experience and Challenges of Reporting in Sierra Leone [Response to Letter]. Baloxavir Resistance Markers in Influenza A and B Viruses in the Americas. Adverse Events Following Immunization with Novel Oral Polio Vaccine Type 2, and the Experience and Challenges of Reporting in Sierra Leone [Letter]. Adverse Drug Reactions Related with Antibiotic Medicines in Malawi: A Retrospective Analysis of Prevalence and Associated Factors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1